<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022188/" ref="ordinalpos=1720&amp;ncbi_uid=2719317&amp;link_uid=PMC3022188" image-link="/pmc/articles/PMC3022188/figure/fig1/" class="imagepopup">Figure 1.  From: Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma. </a></div><br /><div class="p4l_captionBody">Rationale for dual treatment targeting the IGF-1R signaling pathway in RMS.  Rapamycin inhibits mTOR signaling, preventing inhibitory feedback on IRS-1 which allows proliferative signals from IGF-1R to IRS-1, PI3K, and AKT.  Dual treatment using rapamycin in combination with IGF-1R inhibition, such as monoclonal blocking antibodies, prevents signaling to these critical progrowth signaling nodes.</div></div>